Home /Investor Relations

INVESTOR RELATIONS

KEY FIGURES

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions.

In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases.

Kedrion distributes its products in over 100 countries and is the world’s 5th top player in the field of plasma-derived products.

 

 

PRESS RELEASES

1Q26 Earnings Results Call 

Kedrion delivers strong financial performance in 2025

Kedrion SpA reports strong FY 2025 Financial Results

9M 2025 Investor Call

Kedrion SpA reports strong 9M 2025 Financial Results

Kedrion Biopharma receives FDA approval for QIVIGY® and confirms its plan to increase investments in the US throughout its global operations

Kedrion SpA reports strong 1H 2025 Financial Results

Q1 2025 Earnings Results Call

Kedrion SpA approves its 1Q 2025 Financial Results

FY24 Earnings Results Call

FINANCIAL REPORTS

OTHER DOCUMENTS


For more information please contact: [email protected]